Table 3.
Characteristics for four study subjects that had a time to progression of two years or longer
| Case number | ||||
|---|---|---|---|---|
| 1 | 13 | 6 | 2 | |
| BRCA1 mutation | C61G | C61G | 5382insC | 5382insC |
| Age at treatment | 56 | 34 | 48 | 66 |
| Estrogen receptor | Negative | Negative | Positive | Negative |
| Progesterone receptor | Positive | Negative | Positive | Negative |
| HER2 status | Negative | Negative | Negative | Negative |
| Site of metastases | Lung | Lung, liver | Liver | Liver |
| Number of sites of metastases | 1 | 2 | 1 | 1 |
| Prior adjuvant chemotherapy | Yes | Yes | Yes | Yes |
| Line of therapy of metastatic disease | 1 | 3 | 1 | 2 |
| Response | Complete | Complete | Partial | Partial |
| Time from treatment to progression (months) | 36 | 27 | 27 | 28 |